allogeneic K562-GM tumor cell vaccine / National Cancer Institute  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
allogeneic K562-GM tumor cell vaccine / National Cancer Institute
NCT00487305: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma

Active, not recruiting
1
40
US
Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
Dana-Farber Cancer Institute
Follicular Lymphoma
07/23
10/24

Download Options